Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii.

Objective: The rising occurrence of drug-resistant pathogens accentuates the need to identify novel antibiotics. We wanted to identify new scaffolds for drug discovery by repurposing FDA-approved drugs against Acinetobacter baumannii, an emerging Gram-negative nosocomial drug-resistant pathogen.

Materials And Methods: In this study, we screened 1040 FDA-approved drugs against drug-susceptible A.